These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 1471601)

  • 41. Comparison of intravenous anisoylated plasminogen streptokinase activator complex with intracoronary streptokinase in acute myocardial infarction.
    Bonnier JJ
    Drugs; 1987; 33 Suppl 3():151-3. PubMed ID: 3315583
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Comparison of clinical efficacy of thrombolytic drugs in patients with acute myocardial infarction].
    López-Sendón JL
    Rev Esp Cardiol; 1992; 45 Suppl 2():9-20. PubMed ID: 1475514
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Towards improved thrombolytic therapy.
    Collen D
    Lancet; 1993 Jul; 342(8862):34-6. PubMed ID: 8100296
    [No Abstract]   [Full Text] [Related]  

  • 44. Thrombolysis: the need for a critical review.
    Monrad ES
    J Am Coll Cardiol; 1991 Nov; 18(6):1573-8. PubMed ID: 1939963
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Achievement of coronary artery patency by use of anisoylated plasminogen streptokinase activator complex in acute myocardial infarction.
    Hillis WS; Hornung RS; Hogg KJ; Hockings N; Burns JM; Dunn FG
    Drugs; 1987; 33 Suppl 3():117-23. PubMed ID: 3315576
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Intravenous anisoylated plasminogen streptokinase activator complex versus intravenous streptokinase in evolving myocardial infarction. Preliminary data from a randomised multicentre study.
    Brochier ML; Quilliet L; Kulbertus H; Materne P; Letac B; Cribier A; Monassier JP; Sacrez A; Favier JP
    Drugs; 1987; 33 Suppl 3():140-5. PubMed ID: 3315581
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Systemic effects of anisoylated plasminogen streptokinase activator complex and streptokinase therapy in acute myocardial infarction. Coagulation aspects of the Dutch Invasive Reperfusion Study.
    Hoffmann JJ; Bonnier JJ; de Swart JB; Custers P; Vijgen M
    Drugs; 1987; 33 Suppl 3():242-6. PubMed ID: 3315602
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Anisoylated plasminogen streptokinase complex during the acute phase of myocardial infarction. Results of a multicenter double-blind study versus heparin].
    Cassagnes J; Bassand JP; Machecourt J; Lusson JR; Anguenot T; Borel E; Vacher D; Denis B; Maurat JP; Jallut H
    Arch Mal Coeur Vaiss; 1990 Apr; 83(4):453-60. PubMed ID: 2111665
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Creation of the recombinant tissue plasminogen activator (rt-PA) image and its influence on practice habits.
    Sherry S; Marder VJ
    J Am Coll Cardiol; 1991 Nov; 18(6):1579-82. PubMed ID: 1939964
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Controversies in thrombolysis--choice of the agent.
    Horak AR; Commerford PJ
    S Afr Med J; 1990 Jan; 77(2):60-1. PubMed ID: 2104993
    [No Abstract]   [Full Text] [Related]  

  • 51. [Fibrinolytic agents--who benefits when?].
    Weichert W; Seifried E
    Ther Umsch; 1995 Oct; 52(10):652-60. PubMed ID: 7482376
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Prehospital thrombolysis with reteplase: the Nijmegen/Rotterdam study.
    Lamfers EJ; Schut A; Hooghoudt TE; Hertzberger DP; Boersma E; Simoons ML; Verheugt FW
    Am Heart J; 2003 Sep; 146(3):479-83. PubMed ID: 12947366
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Haematological effects of anisoylated plasminogen streptokinase activator complex and streptokinase in patients with acute myocardial infarction. Interim report of the IRS II Study.
    Monassier JP; Hanssen M
    Drugs; 1987; 33 Suppl 3():247-52. PubMed ID: 2445540
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction.
    GUSTO Angiographic Investigators
    N Engl J Med; 1993 Nov; 329(22):1615-22. PubMed ID: 8232430
    [TBL] [Abstract][Full Text] [Related]  

  • 55. After coronary thrombolysis and reperfusion, what next?
    Bang NU; Wilhelm OG; Clayman MD
    J Am Coll Cardiol; 1989 Oct; 14(4):837-49. PubMed ID: 2677087
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Improved left ventricular function in myocardial infarction following intravenous thrombolytic therapy with acylated plasminogen activator.
    Ovsyshcher I; Silber H; Hausman MI; Margolis G; Gueron M
    Angiology; 1990 Feb; 41(2):133-8. PubMed ID: 2407157
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Comparison of the thrombolytic activity of the novel plasminogen activator, LY210825, to anisoylated plasminogen-streptokinase activator complex in a canine model of coronary artery thrombolysis.
    Jackson CV; Frank JD; Craft TJ; Sundboom JL; Smith GF
    J Pharmacol Exp Ther; 1992 Jan; 260(1):64-70. PubMed ID: 1731052
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Comparisons of characteristics and outcomes among women and men with acute myocardial infarction treated with thrombolytic therapy. GUSTO-I investigators.
    Weaver WD; White HD; Wilcox RG; Aylward PE; Morris D; Guerci A; Ohman EM; Barbash GI; Betriu A; Sadowski Z; Topol EJ; Califf RM
    JAMA; 1996 Mar; 275(10):777-82. PubMed ID: 8598594
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Safety and side effects of anisoylated plasminogen streptokinase activator complex and streptokinase in patients with acute myocardial infarction. Interim report of the IRS II Study.
    Monassier JP; Hanssen M
    Drugs; 1987; 33 Suppl 3():282-5. PubMed ID: 3315608
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [The new thrombolytic agents].
    Bassand JP
    Ann Cardiol Angeiol (Paris); 1989 Sep; 38(7 Pt 2):487-91. PubMed ID: 2511796
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.